Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.

Frontiers in immunology - 1 Jan 2021

Lin Jiamao, Wang Xiaohui, Zhang Chenyue, Bu Shuai, Zhao Chenglong, Wang Haiyong

Abstract excerpt

Background: At present, there is a lack of studies focusing on the survival prediction of patients with non-small cell lung cancer (NSCLC) receiving atezolizumab in light of gene mutation characteristic. Methods: Patients with NSCLC receiving atezolizumab from the OAK study were defined as the training group. LASSO Cox regressions were applied to establish the gene mutation signature model to predict the overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Docetaxel

Share to Genomics

Share to Lung Neoplasms

Share to Survival Rate

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 34248926
DOI: 10.3389/fimmu.2021.606027
PMCID: PMC8261129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.PMID 34248926Read ↗

Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.Semantic proximity Read ↗

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.Semantic proximity Read ↗

Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.Semantic proximity Read ↗

EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.Semantic proximity Read ↗

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read ↗

GASPS: A Multi-Omics Framework for Defining Genomic Aberration-Driven Signatures and Predicting Patient Outcomes in Lung CancerSemantic proximity Read ↗

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.Semantic proximity Read ↗

PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.Semantic proximity Read ↗

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor.Semantic proximity Read ↗

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.Semantic proximity Read ↗

Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.Semantic proximity Read ↗

Improving prediction of survival and progression in metastatic non-small cell lung cancer following immunotherapy through machine learning of circulating tumor DNA dynamicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.